Investigating interleukin-37 as a treatment and biomarker for Alzheimer’s disease [ 2017 - ]

Research Grant

Researchers: Dr Rodrigo Medeiros (Principal investigator)

Brief description Alzheimer’s disease (AD) is the defining healthcare condition of our generation. Finding asymptomatic at risk individuals at preclinical stages will allow initiation of therapies that will either slow or, preferably, stop the progression of the disease. Herein, we will study a protein called interleukin-37 as an early biomarker and treatment for AD.

Funding Amount $677,857.00

Funding Scheme Project Grants

Notes New Investigator Grant